Nontraditional cardiovascular risk factors in hemodialysed patients with chronic kidney disease

被引:0
|
作者
Muszynska, Agnieszka [1 ]
Steciwko, Andrzej [1 ,2 ]
Mastalerz-Migas, Agnieszka [1 ,2 ]
Bunio, Andrzej [3 ,4 ]
Pokorna-Kalwak, Dagmara [1 ]
Drobnik, Jaroslaw [1 ,2 ]
机构
[1] AM Wroclawiu, Katedra & Zaklad Med Rodzinnej, Wroclaw, Poland
[2] Panstwowa Med Wyzsza Szkola Zawodowa Opolu, Opole, Poland
[3] Politech Opolskiej, Wydzialu Wychowania Fizycznego & Fizjoterapii, Katedra Nauk Biol, Opole, Poland
[4] Ctr Med Opolu, Stacja Dializ Wojewodzkiego, Oddzial Nefrol, Opole, Poland
关键词
calcium; phosphorus; parathyroid hormone; hemodialysis; KDOQI; 2003; Guidelines;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background. Chronic kidney disease is connected with bone metabolism disorders leading to renal osteodystrophy and increased cardiovascular morality and morbidity. The publication of the KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in CKD in 2003 recommended target levels for such parameters as: albumin-corrected calcium (Caalb), phosphorus (P), parathyroid hormone (iPTH) and calcium-phosphorus product (Ca x P). Objectives. The aim of the present study was to evaluate the achievement of target levels recommended by KDOQI Guidelines in hemodialysed patients. Material and methods. The study group consisted of 80 hemodialysed patients (W - 39%, M - 61%), mean age 61 +/- 13 years (range 19-85), mean duration of HD treatment 43 +/- 41 months. Ca, P and iPTH serum levels were measured and Caalb, Ca x P were calculated. Results. Mean serum Caalb and Ca x P were normal, both in men and women. Mean serum P and iPTH were higher than recommended in KDOQI guidelines. 58% of patients achieved recommended levels of Caalb and Ca x P but only 31% - P and 15% iPTH levels. There were 63% patients who had elevated levels of iPTH. Moreover 15% had iPTH levels over 1000 pg/ml that is connected with high bone turnover and serious bone metabolism disorders. Conclusions. 1. A large percentage of patients do not achieve KDOQI 2003 recommended serum levels of bone metabolism parameters, mainly P and iPTH. 2. Patients with abnormal levels of these parameters are especially exposed to renal osteodystrophy and increased cardiovascular morality and morbidity. 3. Proper treatment is needed to reduce untraditional and typical cardiovascular risk factors in this group of patients.
引用
收藏
页码:547 / 550
页数:4
相关论文
共 50 条
  • [31] Risk factors for urosepsis in chronic kidney disease patients with urinary tract infections
    Dimitrijevic, Zorica
    Paunovic, Goran
    Tasic, Danijela
    Mitic, Branka
    Basic, Dragoslav
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [32] 25 hydroxyvitamin D levels and cardiovascular risk in a cohort of patients with chronic kidney disease
    Garcia-Canton, C.
    Bosch, E.
    Auyanet, I.
    Ramirez, A.
    Rossique, P.
    Culebras, C.
    Sanchez, A.
    Toledo, A.
    Lago, M.
    Esparza, N.
    Checa, M. D.
    NEFROLOGIA, 2010, 30 (04): : 435 - 442
  • [33] Assessing cardiovascular risk in chronic kidney disease patients prior to kidney transplantation: clinical usefulness of a standardised cardiovascular assessment protocol
    Ramphul, Robin
    Fernandez, Maria
    Firoozi, Sam
    Kaski, Juan C.
    Sharma, Rajan
    Banerjee, Debasish
    BMC NEPHROLOGY, 2018, 19
  • [34] Factors associated with survival in dogs with chronic kidney disease
    Rudinsky, Adam J.
    Harjes, Laura M.
    Byron, Julie
    Chew, Dennis J.
    Toribio, Ramiro E.
    Langston, Catherine
    Parker, Valerie J.
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2018, 32 (06): : 1977 - 1982
  • [35] Utility of Nontraditional Risk Markers in Atherosclerotic Cardiovascular Disease Risk Assessment
    Yeboah, Joseph
    Young, Rebekah
    McClelland, Robyn L.
    Delaney, Joseph C.
    Polonsky, Tamar S.
    Dawood, Farah Z.
    Blaha, Michael J.
    Miedema, Michael D.
    Sibley, Christopher T.
    Carr, J. Jeffrey
    Burke, Gregory L.
    Goff, David C., Jr.
    Psaty, Bruce M.
    Greenland, Philip
    Herrington, David M.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (02) : 139 - 147
  • [36] Managing cardiovascular risk factors in patients with chronic kidney disease: pharmacological and non-pharmacological interventions in the Copenhagen CKD Cohort
    Ballegaard, Ellen Linnea Freese
    Carlson, Nicholas
    Jorgensen, Morten Buus
    Sorensen, Ida Maria Hjelm
    Trankjaer, Helene
    Almarsdottir, Anna Birna
    Bro, Susanne
    Feldt-Rasmussen, Bo
    Kamper, Anne-Lise
    CLINICAL KIDNEY JOURNAL, 2024, 17 (07)
  • [37] Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors US Preventive Services Task Force Recommendation Statement
    Curry, Susan J.
    Krist, Alex H.
    Owens, Douglas K.
    Barry, Michael J.
    Caughey, Aaron B.
    Davidson, KarinaW.
    Doubeni, Chyke A.
    Epling, John W., Jr.
    Kemper, Alex R.
    Kubik, Martha
    Landefeld, Seth
    Mangione, Carol M.
    Silverstein, Michael
    Simon, Melissa A.
    Tseng, Chien-Wen
    Wong, John B.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (03): : 272 - 280
  • [38] Biomarkers Determining Cardiovascular Risk in Patients with Kidney Disease
    Siasos, G.
    Tousoulis, D.
    Michalea, S.
    Oikonomou, E.
    Kolia, C.
    Kioufis, S.
    Synetos, A.
    Vlasis, K.
    Papavassiliou, A. G.
    Stefanadis, C.
    CURRENT MEDICINAL CHEMISTRY, 2012, 19 (16) : 2555 - 2571
  • [39] Cardiovascular disease in patients with stage IV and V of chronic kidney disease
    Castellanos Heredia, Jose E.
    Morales Jimenez, Edelsy
    Mayo Salazar, Alexis
    Paez Quevedo, Saili
    INSUFICIENCIA CARDIACA, 2014, 9 (03) : 105 - 111
  • [40] Skin Autofluorescence Is a Predictor of Cardiovascular Disease in Chronic Kidney Disease Patients
    Furuya, Fumihiko
    Shimura, Hiroki
    Takahashi, Kazuya
    Akiyama, Daiichiro
    Motosugi, Ai
    Ikegishi, Yukinobu
    Haraguchi, Kazutaka
    Kobayashi, Tetsuro
    THERAPEUTIC APHERESIS AND DIALYSIS, 2015, 19 (01) : 40 - 44